文章摘要
徐 薇,印晓静,王正芳,刁叶秋,刘海荣.血清肿瘤标志物与宫颈癌病理特征的关系及对术后复发的预测研究[J].,2023,(15):2964-2969
血清肿瘤标志物与宫颈癌病理特征的关系及对术后复发的预测研究
The Relationship between Serum Tumor Markers and Pathological Features of Cervical Cancer and the Prediction of Postoperative Recurrence
投稿时间:2023-02-06  修订日期:2023-02-28
DOI:10.13241/j.cnki.pmb.2023.15.032
中文关键词: 血清肿瘤标志物  宫颈癌病理特征  术后复发  预测价值
英文关键词: Serum tumor markers  Pathological features of cervical cancer  Postoperative recurrence  Predictive value
基金项目:江苏省中医药管理局中医药科技发展计划项目(MS2021079)
作者单位E-mail
徐 薇 扬州大学附属苏北人民医院检验科 江苏 扬州 225000 xw73666@163.com 
印晓静 扬州大学附属苏北人民医院检验科 江苏 扬州 225000  
王正芳 扬州大学附属苏北人民医院检验科 江苏 扬州 225000  
刁叶秋 扬州大学附属苏北人民医院检验科 江苏 扬州 225000  
刘海荣 扬州大学附属苏北人民医院输血科 江苏 扬州 225000  
摘要点击次数: 298
全文下载次数: 238
中文摘要:
      摘要 目的:探讨血清肿瘤标志物与宫颈癌病理特征的关系及对术后复发的预测研究。方法:选择2015年1月至2017年12月来我院诊治的宫颈癌患者82例作为观察组,选择同期来我院体检的健康女性者50例,两组均使用电化学发光免疫分析法检测血清中的CA125、CA153、CA199、CEA水平,观察组患者随访时间截至2022年12月。对比两组血清CA125、CA153、CA199、CEA水平,分析观察组患者血清CA125、CA153、CA199、CEA水平与临床病理特征的关系,分析观察组患者术后随访复发情况,宫颈癌根治术后患者复发的单因素与多因素Cox回归结果,血清CA125、CA153、CA199、CEA水平对宫颈癌根治术后复发的预测价值。结果:观察组的血清CA125、CA153、CA199、CEA水平明显较对照组高(P<0.05)。宫颈癌患者不同FIGO分期、间质浸润深度及是否存在淋巴结转移间血清CA125、CA153、CA199、CEA水平对比有统计学意义(P<0.05)。82例患者随访时间为13~60个月,中位生存时间为39个月,截止2022年12月末次随访,82例患者术后复发18例(21.95%)。单因素及多因素Cox回归分析表明,FIGO分期在ⅡA期、间质浸润深度≥1/2、有淋巴结转移、CA125≥307.41 U/mL、CA153≥185.89 U/mL、CA199≥153.23 U/mL、CEA≥30.15 ng/mL是影响宫颈癌术后复发的独立危险因素。ROC曲线显示,CA125+CA153+CA199+CEA预测宫颈癌术后复发的AUC明显较CA125、CA153、CA199、CEA单独指标预测价值高(P<0.05)。结论:宫颈癌患者血清CA125、CA153、CA199、CEA高表达,其与间质浸润深度、FIGO 分期、淋巴结转移、术后复发有关,四者联合可作为宫颈癌术后复发的预测指标。
英文摘要:
      ABSTRACT Objective: To investigate the relationship between serum tumor markers and pathological features of cervical cancer and the prediction of postoperative recurrence. Methods: 82 patients with cervical cancer who came to our hospital from January 2015 to December 2017 were selected as the observation group, and 50 healthy women who came to our hospital for physical examination during the same period were selected. The serum levels of CA125, CA153, CA199 and CEA in both groups were detected by electrochemical luminescence immunoassay. Patients in the observation group were followed up until December 2022. The serum CA125, CA153, CA199, CEA levels of the two groups were compared, and the relationship between the serum CA125, CA153, CA199, CEA levels and clinicopathological characteristics of the observation group was analyzed. The recurrence of patients in the observation group was analyzed after the postoperative follow-up, and the univariate and multivariate Cox regression results of the recurrence of patients after radical resection of cervical cancer were analyzed. Prognostic value of serum CA125, CA153, CA199 and CEA levels for recurrence of cervical cancer after radical resection. Results: The levels of serum CA125, CA153, CA199 and CEA in observation group were significantly higher than those in control group (P<0.05). The levels of serum CA125, CA153, CA199 and CEA among patients with cervical cancer at different FIGO stages, depth of interstitial invasion and presence of lymph node metastasis were statistically significant (P<0.05). The follow-up time of 82 patients was 13-60 months, and the median survival time was 39 months. By the end of December 2022, 18 of 82 patients (21.95%) had relapse after surgery. Univariate and multivariate Cox regression analysis showed that FIGO stage in stage ⅡA, interstitial infiltration depth≥1/2, lymph node metastasis, CA125≥307.41U/mL, CA153≥185.89U/mL, CA199≥153.23U/mL, CEA≥30.15ng/mL are independent risk factors for postoperative recurrence of cervical cancer.ROC curve showed that the AUC value of CA125+CA153+CA199+CEA in predicting postoperative recurrence of cervical cancer was significantly higher than that of CA125, CA153, CA199 and CEA alone (P<0.05). Conclusion: Serum CA125, CA153, CA199 and CEA are highly expressed in patients with cervical cancer, which is related to the depth of interstitial infiltration, FIGO stage, lymph node metastasis and postoperative recurrence. The combination of the four can be used as a predictor of postoperative recurrence of cervical cancer.
查看全文   查看/发表评论  下载PDF阅读器
关闭